Clinical Breast Cancer, Journal Year: 2025, Volume and Issue: unknown
Published: April 1, 2025
Language: Английский
Annals of Oncology, Journal Year: 2023, Volume and Issue: 34(11), P. 970 - 986
Published: Sept. 6, 2023
The 18th St Gallen International Breast Cancer Conference held in March 2023, Vienna, Austria, assessed significant new findings for local and systemic therapies early breast cancer with a focus on the evaluation of multimodal treatment options. emergence more effective, innovative agents both preoperative (primary or neoadjuvant) post-operative (adjuvant) settings has underscored pivotal role multidisciplinary approach decision making, particularly when selecting therapy an individual patient. importance discussions regarding clinical benefits interventions was explicitly emphasized by consensus panel as integral part developing optimal plan 'right' degree intensity duration. panelists focused controversies surrounding management common ductal/no special type lobular histology, which account vast majority tumors. expert opinion based interpretations available data, well current practices their professional environments, personal socioeconomic factors affecting patients, cognizant varying reimbursement accessibility constraints around world. strongly advocated patient participation well-designed studies whenever feasible. With these considerations mind, Consensus aims to offer guidance clinicians appropriate treatments early-stage assist balancing realistic trade-offs between benefit toxicity, enabling patients make well-informed choices through shared decision-making process.
Language: Английский
Citations
108
Signal Transduction and Targeted Therapy, Journal Year: 2025, Volume and Issue: 10(1)
Published: Feb. 18, 2025
Abstract Breast cancer, characterized by unique epidemiological patterns and significant heterogeneity, remains one of the leading causes malignancy-related deaths in women. The increasingly nuanced molecular subtypes breast cancer have enhanced comprehension precision treatment this disease. mechanisms tumorigenesis progression been central to scientific research, with investigations spanning various perspectives such as tumor stemness, intra-tumoral microbiota, circadian rhythms. Technological advancements, particularly those integrated artificial intelligence, significantly improved accuracy detection diagnosis. emergence novel therapeutic concepts drugs represents a paradigm shift towards personalized medicine. Evidence suggests that optimal diagnosis models tailored individual patient risk expected are crucial, supporting era oncology for cancer. Despite rapid advancements increasing emphasis on clinical comprehensive update summary panoramic knowledge related disease needed. In review, we provide thorough overview global status including its epidemiology, factors, pathophysiology, subtyping. Additionally, elaborate latest research into contributing progression, emerging strategies, long-term management. This review offers valuable insights Cancer Research, thereby facilitating future progress both basic application.
Language: Английский
Citations
17
Cancer Letters, Journal Year: 2024, Volume and Issue: 588, P. 216740 - 216740
Published: Feb. 27, 2024
Language: Английский
Citations
15
New England Journal of Medicine, Journal Year: 2024, Volume and Issue: unknown
Published: Dec. 12, 2024
BackgroundWhether surgical axillary staging as part of breast-conserving therapy can be omitted without compromising survival has remained unclear.MethodsIn this prospective, randomized, noninferiority trial, we investigated the omission surgery compared with sentinel-lymph-node biopsy in patients clinically node-negative invasive breast cancer staged T1 or T2 (tumor size, ≤5 cm) who were scheduled to undergo surgery. We report here per-protocol analysis disease–free (the primary efficacy outcome). To show surgery, 5-year rate had at least 85%, and upper limit confidence interval for hazard ratio disease death below 1.271.ResultsA total 5502 eligible (90% clinical 79% pathological cancer) underwent randomization a 1:4 ratio. The population included 4858 patients; 962 assigned treatment surgery-omission group), 3896 group). median follow-up was 73.6 months. estimated 91.9% (95% [CI], 89.9 93.5) among group 91.7% CI, 90.8 92.6) group, 0.91 0.73 1.14), which prespecified margin. first primary-outcome events (occurrence recurrence from any cause), occurred 525 (10.8%), showed apparent differences between incidence (1.0% vs. 0.3%) (1.4% 2.4%). safety indicates that lower lymphedema, greater arm mobility, less pain movement shoulder than biopsy.ConclusionsIn trial involving node-negative, cancer), noninferior after 6 years. (Funded by German Cancer Aid; INSEMA ClinicalTrials.gov number, NCT02466737.)
Language: Английский
Citations
15
The Breast, Journal Year: 2024, Volume and Issue: 74, P. 103674 - 103674
Published: Jan. 27, 2024
This narrative work highlights a selection of published from 2023 with potential implications for breast cancer practice. We feature publications that have provided new knowledge immediately relevant to patient care or future research. also highlight guidelines reported evidence-based consensus recommendations support practice and evaluation in diagnosis treatment. The scope selected represents various domains disciplines control, prevention treatment early advanced cancer.
Language: Английский
Citations
10
The Lancet Oncology, Journal Year: 2024, Volume and Issue: 25(3), P. e114 - e125
Published: Feb. 26, 2024
Language: Английский
Citations
9
Breast Care, Journal Year: 2024, Volume and Issue: 19(3), P. 165 - 182
Published: Jan. 1, 2024
<b><i>Introduction:</i></b> Each year the interdisciplinary AGO (Arbeitsgemeinschaft Gynäkologische Onkologie, German Gynecological Oncology Group) Breast Committee on Diagnosis and Treatment of Cancer provides updated state-of-the-art recommendations for early metastatic breast cancer. <b><i>Methods:</i></b> The evidence-based treatment cancer have been released in March 2024. <b><i>Results Conclusion:</i></b> This paper concisely captures chapter by chapter.
Language: Английский
Citations
9
Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)
Published: Feb. 15, 2025
Abstract Contrast-enhanced ultrasound (CEUS) plays a pivotal role in the diagnosis of primary breast cancer and axillary lymph node (ALN) metastasis. However, imaging features that are clinically crucial for metastasis have not been fully elucidated. Hence, we developed bimodal model to predict ALN patients with early by integrating CEUS images annotated features. The adopted light-gradient boosting machine produce feature importance, enabling extraction In this retrospective study, diagnostic performance was investigated using 788 ALNs obtained from who underwent surgery between 2013 2021, ground truth defined pathological diagnosis. results indicated test cohort had an area under receiver operating characteristic curve (AUC) value 0.93 (95% confidence interval: 0.88, 0.98). accuracy 0.93, which higher than radiologist’s (accuracy 0.85). most important were heterogeneous enhancement, diffuse cortical thickening, eccentric thickening. Our has excellent performance, extracted could be confirming clinical settings.
Language: Английский
Citations
1
Cancers, Journal Year: 2025, Volume and Issue: 17(5), P. 798 - 798
Published: Feb. 26, 2025
Despite advancements in breast cancer surgery, the decision-making process for axillary treatment remains complex, necessitating new predictors like tumor size to Ki67 proliferation index ratio. Intraoperative examination of sentinel lymph node is performed reduce risk a secondary surgery. Several studies have demonstrated that even presence moderate nodal involvement, local disease control can be achieved by omitting dissection (ALND). The aim our retrospective study compare patients subjected biopsy (SNLB) with or without intraoperative evaluation. This included who underwent breast-conserving surgery and SNLB. Of 551 patients, 333 (60.4%) an SNLB evaluation (SLNB-IE), while 218 (39.6%) diagnostic (SLNB-DE). Our analysis revealed ratio independent predictive factor burden, suggesting its utility surgical decision-making. A ALND was 2 (0.6%) vs. 7 (2.8%), p = 0.032, 1 (0.4%) 4 (2.1%), 0.171, excluding T ≥ 2. Surgical time significantly shorter (p > 0.001) SLNB-DE group. According multivariate analysis, lesion dimension (OR 1.678; 95%CI 1.019-2.145; WALD:7.588; 0.006) 0.08; 0.011-0.141; WALD:11.004 were both factors higher burden. value 0.425, which index, identified as predictor burden axilla (sensitivity, 78%; specificity, 87.5%). may omitted but could considered potential candidates cyclin inhibitor cN0 therapy order avoid
Language: Английский
Citations
1
Breast Care, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 30
Published: March 8, 2025
Optimal management of breast cancer requires a multidisciplinary strategy. Each year the interdisciplinary AGO Breast Committee provides updated state-of-the-art recommendations on prevention, diagnosis and treatment cancer. This update follows defined algorithm. The most recent relevant publications are reviewed scientific validity is scored according to Oxford Level evidence (LoE). strength recommendation determined by Grades (GR) recommendation. for EBC MBC have been released in March 2025. paper captures EBC. slides with annotated speeches patient forum available on-demand library (httpas://www.ago.2025.de). Chapters without changes content not included this manuscript.
Language: Английский
Citations
1